LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

LLY

1,013.62

+2.58%↑

JNJ

230.14

+1.18%↑

ABBV

214.4

+2.42%↑

UNH

392.17

+1.15%↑

AZN

185.66

+0.71%↑

Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Abierto

SectorSanidad

21.75 -1.14

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.42

Máximo

22.13

Métricas clave
By Trading Economics
Ingresos	-55M 187M
Ventas	-20M 98M
P/B Media del Sector	3.597 51.415
BPA	0.468
Margen de beneficios	190.415
Empleados	159
EBITDA	-160M 48M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+57.49% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-40M 1.7B
Apertura anterior	22.89
Cierre anterior	21.75

Noticias sobre sentimiento de mercado

By Acuity

50%

157 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

18.57 / 18.75 Soporte y Resistencia

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 may 2026, 23:10 UTC

Acciones populares

Stocks to Watch: Agilysys, XP

18 may 2026, 18:44 UTC

Principales Movimientos del Mercado

Claritev Shares Recover After Comments About DOJ

18 may 2026, 23:55 UTC

Ganancias

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 may 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 may 2026, 23:37 UTC

Charlas de Mercado

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 may 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 may 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

18 may 2026, 20:25 UTC

Ganancias

Correct: XP 1Q Total Client Assets BRL1.53T

18 may 2026, 20:23 UTC

Ganancias

XP 1Q Total Client Assets BRL1.53B

18 may 2026, 20:19 UTC

Ganancias

XP 1Q Adj EPS BRL2.49 >XP

18 may 2026, 20:19 UTC

Ganancias

XP 1Q Rev BRL4.73B >XP

18 may 2026, 19:10 UTC

Charlas de Mercado

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 may 2026, 19:00 UTC

Ganancias

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 may 2026, 18:52 UTC

Charlas de Mercado

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 may 2026, 18:17 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 may 2026, 17:22 UTC

Charlas de Mercado

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 may 2026, 16:57 UTC

Adquisiciones, fusiones, absorciones

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 may 2026, 16:57 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

18 may 2026, 16:57 UTC

Charlas de Mercado

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 may 2026, 16:54 UTC

Adquisiciones, fusiones, absorciones

Vinci Doesn't Set Out Financial Details of Deal

18 may 2026, 16:50 UTC

Adquisiciones, fusiones, absorciones

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 may 2026, 16:49 UTC

Adquisiciones, fusiones, absorciones

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 may 2026, 16:49 UTC

Adquisiciones, fusiones, absorciones

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 may 2026, 16:48 UTC

Adquisiciones, fusiones, absorciones

Vinci Buys Canada's Modern Group of Companies

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

57.49% repunte

Estimación a 12 Meses

Media 34.6 USD 57.49%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

18.57 / 18.75Soporte y Resistencia

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

157 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.